Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1,74%
1 094,84
+18,71
+1,74%
—1 076,131 079,891 100,771 079,89——
SIXC
Communications
SIXC
Communications
SIXC
-0,42%
604,21
-2,53
-0,42%
—606,74606,74607,90602,03——
SIXE
Energy
SIXE
Energy
SIXE
+0,07%
1 249,71
+0,89
+0,07%
—1 248,821 246,371 256,421 239,08——
SIXI
Industrials
SIXI
Industrials
SIXI
+0,86%
1 739,26
+14,90
+0,86%
—1 724,361 733,021 745,751 727,76——
SIXM
Financials
SIXM
Financials
SIXM
+0,01%
635,63
+0,040
+0,01%
—635,59635,08637,96633,31——
SIXR
Staples
SIXR
Staples
SIXR
+0,61%
848,32
+5,17
+0,61%
—843,15842,50852,77840,85——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0,22%
216,76
+0,47
+0,22%
—216,29216,29217,30215,24——
SIXT
Technology
SIXT
Technology
SIXT
+2,20%
3 335,14
+71,73
+2,20%
—3 263,413 296,253 343,663 295,42——
SIXU
Utilities
SIXU
Utilities
SIXU
+0,01%
939,34
+0,10
+0,01%
—939,24941,57948,11939,11——
SIXV
Health care
SIXV
Health care
SIXV
+0,38%
1 468,17
+5,61
+0,38%
—1 462,561 465,031 471,561 459,66——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,28%
2 387,09
+6,69
+0,28%
—2 380,402 394,922 412,132 386,82——
GIS:FRA
Gilead Sciences, Inc
€113,18
-0,25%
(-0,28) 1D
5 Mei, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for GIS...
Open
€113,70
High
€113,70
Low
€113,18
Mkt. cap
165,68 mjd
Avg. vol.
330,00
Volume
298,00
52-wk high
€132,00
52-wk low
€82,61
No. of employees
17 k
News stories
From sources across the web
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. It has recently expanded into different therapeutic areas such as oncology and inflammation. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17 k
Founded22 Jun. 1987
HeadquartersFoster City, Kalifornië, Verenigde State van Amerika
Sector-
Websitegilead.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mrt. 2025
Jun. 2025
Sep. 2025
Des. 2025
Revenue
6,67 mjd
7,08 mjd
7,77 mjd
7,92 mjd
Cost of goods sold
1,54 mjd
1,50 mjd
1,57 mjd
1,62 mjd
Cost of revenue
1,54 mjd
1,50 mjd
1,57 mjd
1,62 mjd
Research and development expenses
1,34 mjd
1,45 mjd
1,33 mjd
1,57 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,22 mjd
1,36 mjd
1,35 mjd
1,78 mjd
Operating expense
2,56 mjd
2,81 mjd
2,69 mjd
3,34 mjd
Total operating expenses
4,10 mjd
4,31 mjd
4,26 mjd
4,96 mjd
Operating income
2,57 mjd
2,77 mjd
3,51 mjd
2,96 mjd
Other non operating income
11,00 m
13,00 m
-23,00 m
51,00 m
EBT including unusual items
1,65 mjd
2,43 mjd
3,64 mjd
2,08 mjd
EBT excluding unusual items
2,40 mjd
2,58 mjd
3,34 mjd
2,80 mjd
Income tax expense
334,00 m
468,00 m
589,00 m
-105,00 m
Effective tax rate
20,25%
19,28%
16,18%
-5,05%
Other operating expenses
-
-
-
-
Net income
1,32 mjd
1,96 mjd
3,05 mjd
2,18 mjd
Net profit margin
19,72%
27,68%
39,28%
27,55%
Earnings per share
1,81
2,01
2,47
1,86
Interest and investment income
94,00 m
73,00 m
88,00 m
95,00 m
Interest expense
-260,00 m
-254,00 m
-256,00 m
-255,00 m
Net interest expenses
-166,00 m
-181,00 m
-168,00 m
-160,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
3,26 mjd
3,46 mjd
4,20 mjd
3,65 mjd
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer